MetaCap

Grace Therapeutics (GRCE) vs Pliant Therapeutics (PLRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Grace Therapeutics (GRCE) has outperformed Pliant Therapeutics (PLRX) over the past year, losing 46.4% versus a loss of 61.6%. Over five years, GRCE leads with a -79.3% price change compared with -95.9% for PLRX. Pliant Therapeutics is the larger company by market cap ($36.9 million vs $36.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

GRCE-46.39%PLRX-61.61%
+67%-0%-68%
Nov 21, 20251 yearNov 20, 2026
GRCE-80.48%PLRX-96.03%
+144%+18%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

GRCE versus PLRX key metrics
MetricGRCEPLRX
Share price$1.71$0.5951
Market cap$35.97M$36.89M
1-day change-0.58%-4.02%
YTD return-50.58%-51.22%
1-year return-46.39%-61.61%
5-year return-79.35%-95.89%
EPS (TTM)$-1.16$-1.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-7.79M$-149.34M
52-week high$5.18$1.67
52-week low$1.64$0.5719
Distance from 52-week high-66.99%-64.37%
Analyst consensusnonenone
Avg. price target upside+243.27%+236.08%
Average volume119.27K408.93K
Shares outstanding21.04M61.99M
Employees549
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • GRCE has outperformed PLRX by 15.2 percentage points over the past year.

About Grace Therapeutics

GRCE stock →

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

GRCE vs PLRX FAQ

Which is bigger, Grace Therapeutics or Pliant Therapeutics?

Pliant Therapeutics (PLRX) is larger, with a market capitalization of $36.89M compared with $35.97M for Grace Therapeutics (GRCE).

Which stock has performed better over the past year, GRCE or PLRX?

GRCE returned -46.39% over the past 12 months, compared with -61.61% for PLRX (price return, excluding dividends). Past performance does not predict future results.

Are Grace Therapeutics and Pliant Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons